Show simple item record

dc.contributor.authorFernández López, Cristina
dc.contributor.authorCalleja Hernández, Miguel Ángel 
dc.contributor.authorEspín Balbino, Jaime
dc.contributor.authorCabeza Barrera, José
dc.contributor.authorExpósito Hernández, José 
dc.date.accessioned2020-05-07T11:52:34Z
dc.date.available2020-05-07T11:52:34Z
dc.date.issued2019
dc.identifier.citationFernández‐López, C., Calleja‐Hernández, M. Á., Balbino, J. E., Cabeza‐Barrera, J., & Expósito‐Hernández, J. (2019). Trends in endpoint selection and result interpretation in advanced non‐small cell lung cancer clinical trials published between 2000 and 2012: A retrospective cohort study. Thoracic cancer, 10(4), 904-908.es_ES
dc.identifier.urihttp://hdl.handle.net/10481/61869
dc.description.abstractBackground: The objective of this review was to investigate trends in clinical trial design, specifically, the primary outcomes used, interpretation of results, and the magnitude of the benefits described in phase III controlled clinical trials in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). Methods: Seventy-six trials published between 2000 and 2012 were selected from a total of 122 identified in a structured search. Results: Overall survival (OS) was evaluated as the primary study endpoint in 50 (65.8%) trials, followed by progression-free survival (PFS) in 15 (19.7%), and other variables, such as toxicity, quality of life (QoL), and response rate in 11 (14.5%). Ten (66.7%) out of 15 clinical trials using PFS as the primary endpoint were published between 2010 and 2012. Median overall survival (mOS) was 9.90 months (interquartile range: 3.5) with an increase of 0.384 months per year of publication (P < 0.001). A statistically significant improvement in mOS was obtained in only 13 (18.8%) trials. A total of 41 (53.9%) studies concluded that the result was positive. Of these, only 16 (39.1%) showed a statistically significant benefit in OS. QoL was assessed in 46 trials (60.5%) and of these, 10 (21.7%) reported significant improvements. Conclusions: These findings raise important questions about how clinical benefits are measured in clinical trials in advanced NSCLC. Appropriate clinically relevant outcome variables should be established and validated, and post-marketing studies should be requested by regulatory authorities to ensure meaningful clinical benefits in OS and QoL.es_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.rightsAtribución-NoComercial 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/es/*
dc.subjectNon-small-cell lung canceres_ES
dc.subjectOutcome assessment (health care)es_ES
dc.subjectQuality of life es_ES
dc.subjectRetrospective studyes_ES
dc.subjectSurvival analysis (Biometry) es_ES
dc.titleTrends in endpoint selection and result interpretation in advanced non-small cell lung cancer clinical trials published between 2000 and 2012: A retrospective cohort studyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1111/1759-7714.13024


Files in this item

[PDF]

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial 3.0 España